Anixa Biosciences to present Phase 1 ovarian cancer CAR-T trial at ESMO Congress

ANIX•2026-11-04

Anixa Biosciences will present Phase 1 ovarian cancer CAR-T trial findings on December 14, 2026, at an immuno-oncology congress in London. The study has reported no dose-limiting toxicities; treatment of the fifth patient cohort is complete, and a higher-dose sixth cohort is planned pending safety verification.

Anixa Biosciences to present Phase 1 ovarian cancer CAR-T trial at ESMO Congress

1. Trial findings presentation

Related News

Revolve Group target price cut to $26 from $27 by UBS

MGE Energy posts Q3 2026 operating revenues of $190.4 million

Trimble falls after Q3 revenue miss, softer ARR growth

Qualcomm signs major 5G infrastructure deal with SpaceX for Starlink Mobile network

SpaceX selects Qualcomm for Starlink Mobile’s nationwide US 5G network